Login
Home / RGIN : OTC
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Regenicin, Inc.

$0 -$0.00 (-66.67%)
OTC · 11 Sep 2026 20:00 UTC
Previous Close
$0
Day Range
$0 - $0
Year Range
$0$0.75
Market Cap
15.35K
AVG Volume
92.5K
Trailing/Forward PE
-0.02/-
PEG ratio
0
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (USD)
00.250.50.75121 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
Net Income (USD)
-400K-300K-200K-100K021 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
Operating Income (USD)
-400K-300K-200K-100K021 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
EBITDA (USD)
-400K-300K-200K-100K021 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
Cash Flows (USD)
-400K-300K-200K-100K021 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
EPS (USD)
-0-0-0021 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
Expenses (USD)
0100K200K300K400KR&DSG&ACapex21 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
Cash & Debt (USD)
05M10M15MCashShort Term Debt21 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
Debt ratios
-50510152021 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
Margins
0%50%100%150%12 Q4
Return on Capital
0%2%4%6%21 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
Shares Outstanding
050M100M150M200M21 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
Book Value Per Share (USD)
-0.06-0.04-0.02021 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
Total Assets (USD)
05M10M15M21 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
Employee Count
012342013201420152016201720182019202020212022
PE Ratio
051015med 0.6Jan 15Apr 15Jun 15Aug 15Oct 15Dec 15Feb 16
Free Cash Flow Yield
-600000%-400000%-200000%0%med -4562.19%Jan 25May 25Sep 25Jan 26May 26Sep 26
Price to Sales
100200300400med 238.68Sep 13Sep 13Oct 13Nov 13Nov 13Dec 13Jan 14
EV/EBITDA
00.511.5med 0.57Mar 15May 15Jul 15Aug 15Oct 15Dec 15Feb 16
Price to Book
02468med 3.87Mar 15May 15Jun 15Aug 15Oct 15Nov 15Jan 16
Regenicin, Inc.
RGIN
Stockpicker

Video analysis: RGIN

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: RGIN

Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrast

defenseworld.net · 24 Aug 2026

Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrast

Regenicin (OTCMKTS:RGIN - Get Free Report) and Monopar Therapeutics (NASDAQ: MNPR - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Profitability This table compares Regenicin and Monopar Therapeutics' net

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.